Merck's Winrevair Cuts Clinical Worsening Risk By 76% Among Hypertension Patients - Merck & Co (NYSE:MRK)

Merck's Winrevair Cuts Clinical Worsening Risk By 76% Among Hypertension Patients - Merck & Co (NYSE:MRK)

Merck reported Phase 3 results showing Winrevair significantly reduced clinical worsening in pulmonary arterial hypertension patients.

Merck makes the case for PAH drug Winrevair in patients with earlier disease

Merck's pulmonary arterial hypertension drug Winrevair cut the risk of “clinical worsening” — an endpoint made up of a variety of signs showing that a patient's illness is progressing — by 76% in recently diagnosed patients. ...